A screening for the candidate diseases that could benefit from immunotherapy

• Published in: Human & veterinary medicine Vol. 13; no. 2; pp. 67 - 69
• Main Authors: Pitu, Flaviu, Pasca, Sergiu, Curca, Razvan, Hajjar, Nadim Al
• Format: Journal Article
• Language: English
• Published: Cluj-Napoca Bioflux SRL 01.06.2021
• Subjects: Cancer therapies; Clinical trials; Colon cancer; Colorectal cancer; Drugs; Endometrium; Gastric cancer; Genomic instability; Hospitals; Immunotherapy; Medical prognosis; Medicine; Melanoma; Metastases; Metastasis; Microsatellite instability; Patients; Pharmacy; Surgery; Survival analysis; Romania
• ISSN: 2066-7655

Objective: Genomic instability is one of the hallmarks of cancer and has seen an increased interest in the last decades due to its capability to predict the response to immunotherapy. The aim of the current study was to determine the microsatellite instability (MSI) on a local cohort and, on the diseases that present Microsatellite Instability High (MSI-H), to further evaluate the efficacy of these drugs on a publicly available cohort. Material and Method: This was a cross-sectional, observational and analytical study in which we included the patients from our institution and also from the TMB and Immunotherapy online cohort. Results: In the current study we observed that the most relevant cases for which we could implement immunotherapy in the treatment of MSI high patients are represented by the colon cancer cases. This is supported by the fact that colon cancer patients represent the highest percentage of malignancies we treat in our unit, which have a clinically relevant prevalence of MSI high. Conclusion: Thus, in the current study we observed that immunotherapy might be a useful tool in the treatment of metastatic colon cancer in our unit.